Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Novo Nordisk A/S Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

With sales of Novo Nordisk’s obesity blockbuster Wegovy more than doubling in 2024’s fourth quarter, the Danish drugmaker feels confident that it can maintain its edge over chief rival Eli ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

By contrast, Novo Nordisk is both the developer and seller of Wegovy, while Viking Therapeutics's VK2735 has posted impressive results in testing and is now in the later stages of development. Wegovy ...